Research Article

Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin

Table 2

Effects of policosanol on plasma proprotein convertase subtilisin/kexin type 9, uric acid, and lipid parameters in two protocols.

VariableI. Patients with atherosclerosisII. Healthy volunteers
Atorvastatin
()
Policosanol +
atorvastatin ()
Control
()
Policosanol
()
Baseline8 weeksBaseline8 weeksBaseline12 weeksBaseline12 weeks

PCSK9 (ng/ml; mean ± SD)256 ± 84357 ± 101$264 ± 60310 ± 86274 ± 77255 ± 54289 ± 71235 ± 46#
Uric acid (mol/L; mean ± SD)360 ± 70377 ± 67332 ± 66320 ± 89323 ± 77322 ± 76344 ± 115288 ± 98*
Total cholesterol
(mmol/L; mean ± SD)
4.91 ± 0.913.61 ± 0.85$4.75 ± 0.783.35 ± 0.66$5.23 ± 0.545.10 ± 0.944.94 ± 0.774.72 ± 1.00
Triglycerides (mmol/L; mean ± SD)1.95 ± 0.781.46 ± 0.62$1.77 ± 1.201.31 ± 0.83*1.59 ± 0.961.41 ± 0.761.12 ± 0.470.94 ± 0.15
HDL-C (mmol/L; mean ± SD)1.04 ± 0.230.98 ± 0.261.16 ± 0.271.12 ± 0.211.31 ± 0.421.35 ± 0.401.61 ± 0.461.54 ± 0.40
LDL-C (mmol/L; mean ± SD)3.12 ± 0.891.97 ± 0.78$2.98 ± 0.751.87 ± 0.54$2.94 ± 0.503.16 ± 0.892.57 ± 0.672.78 ± 0.83
Apoprotein AI (g/L; mean ± SD)1.61 ± 0.311.35 ± 0.341.46 ± 0.271.31 ± 0.341.71 ± 0.361.67 ± 0.321.87 ± 0.401.71 ± 0.26
Apoprotein B (g/L; mean ± SD)1.29 ± 0.380.75 ± 0.26$1.08 ± 0.230.65 ± 0.22$0.83 ± 0.120.88 ± 0.200.70 ± 0.110.76 ± 0.15
Free fatty acid (mmol/L; mean ± SD) 0.50 ± 0.120.62 ± 0.200.36 ± 0.130.32 ± 0.250.39 ± 0.140.38 ± 0.130.49 ± 0.420.45 ± 0.16

< 0.05 versus baseline; $ < 0.01 versus baseline; # = 0.069 versus baseline.
PCSK9, proprotein convertase subtilisin/kexin type 9; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.